Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
33272913
Public Release Type:
Journal
Publication Year: 2020
Affiliation: Department of Epidemiology and Biostatistics, University of California, San Francisco, California.; Departments of Medicine and Anesthesia, University of California, San Francisco, California.; Division of Nephrology, University of California, San Francisco School of Medicine, San Francisco, California.; Division of Nephrology, University of California, San Francisco School of Medicine, San Francisco, California.; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.; Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.; Department of Medicine, Epidemiology and Biostatistics, Western University, London, Ontario, Canada.; Division of Nephrology, University of Washington, Seattle, Washington.; Division of Nephrology and Hypertension and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee.; Renal Section, Veterans Affairs New York Harbor Healthcare System and New York University School of Medicine, New York, New York.; Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.; Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.; Division of Nephrology and Hypertension and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee.; Departments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.; Division of Nephrology, University of California, San Francisco School of Medicine, San Francisco, California.
DOI:
https://doi.org/10.2215/CJN.10840720
Authors:
Brar Sandeep, Liu Kathleen D, Go Alan S, Hsu Raymond K, Chinchilli Vernon M, Coca Steven G, Garg Amit X, Himmelfarb Jonathan, Ikizler T Alp, Kaufman James, Kimmel Paul L, Parikh Chirag R, Siew Edward D, Ware Lorraine B, Zeng Hui, Hsu Chi-Yuan
Request IDs:
20898
,
21425
,
22361
Studies:
Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury
The risk-benefit ratio of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after AKI may be altered due to concerns regarding recurrent AKI. We evaluated, in a prospective cohort, the association between use (versus nonuse) of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and the subsequent risk of AKI and other adverse outcomes after hospitalizations with and without AKI.
